Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 2/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | CASP9 | P55211 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553556 | 0.88 | CTSK (0.65) | SYKCTSKCTSBCTSLCTSS | |
| SCHEMBL11657615 | 0.87 | SYK (0.59) | SYKCTSKCTSBCTSLCTSS | |
| SCHEMBL20885259 | 0.87 | SYK (0.59) | SYKCTSKCTSBCTSLCTSS | |
| SCHEMBL25908075 | 0.87 | SYK (0.57) | SYKCTSKCTSBCTSLCTSS | |
| SCHEMBL8141342 | 0.85 | CTSK (0.56) | SYKCTSKCTSBCTSSCASP3 | |
| SCHEMBL21684844 | 0.85 | CTSK (0.56) | SYKCTSKCTSBCTSSCASP3 | |
| SCHEMBL6279109 | 0.85 | CTSK (0.56) | SYKCTSKCTSBCTSSCASP3 | |
| SCHEMBL20046452 | 0.85 | CA2 (0.58) | SYKCTSKCTSBCTSLCTSS | |
| SCHEMBL20075956 | 0.85 | CA2 (0.58) | SYKCTSKCTSBCTSLCTSS | |
| SCHEMBL12873000 | 0.85 | KLK5 (0.57) | SYKCTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | SYK 3830/4885CTSK 2701/4885CTSB 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.